European Pharmaceutical Review

AUGUST 21, 2023

Submission for US FDA regulatory approval, anticipated to be received by the end of 2023, further drove this progress, GlobalData noted. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted.

Biopharma 98

Biopharma Marketing Sales Medicine 98

pharmaphorum

SEPTEMBER 30, 2022

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. Viatris is seeking FDA approval to market generic versions of both Januvia and Janumet in the US. The US patent (No.

Marketing 59

Marketing Sales Competition FDA 59

Pharmaceutical Technology

JUNE 13, 2023

According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications. It received fast track and breakthrough designation from the FDA and is poised to be first to market.

Patients 52

Patients Sales Competition Safety 52

Pharmaceutical Technology

APRIL 24, 2023

While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023. billion in 2029, while Calquence is expected to make $5.31 billion in 2029.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Management 105

Management Manufacturing Sales Competition 105

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The potential increase in industry competition could also spell trouble for some.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Pharmaceutical Technology

MAY 16, 2023

million by 2029. Although Sanofi may face generic drug competition this year for its multiple sclerosis drug, Aubagio, the company is expected to maintain their sales of Dupixent, accounting for 43.3% Sanofi and Regeneron’s market capitalisation grew by 12.4%

Marketing 52

Marketing Sales Pharma Leads 52